Marc Buyse
Marc Buyse
Chief Scientific Officer, IDDI
Verified email at - Homepage
Cited by
Cited by
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
C Tournigand, T André, E Achille, G Lledo, M Flesh, D Mery-Mignard, ...
Journal of Clinical Oncology 22 (2), 229-237, 2004
Adjuvant trastuzumab in HER2-positive breast cancer
D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ...
New England journal of medicine 365 (14), 1273-1283, 2011
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
C Sotiriou, P Wirapati, S Loi, A Harris, S Fox, J Smeds, H Nordgren, ...
Journal of the National Cancer Institute 98 (4), 262-272, 2006
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 379 (9814), 432-444, 2012
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
M Buyse, S Loi, L Van't Veer, G Viale, M Delorenzi, AM Glas, ...
Journal of the National Cancer Institute 98 (17), 1183-1192, 2006
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women …
P McGale, C Correa, D Cutter, F Duane, M Ewertz, R Gray, G Mannu, ...
The Lancet 383 (9935), 2127-35, 2014
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases
U Pastorino, M Buyse, G Friedel, RJ Ginsberg, P Girard, P Goldstraw, ...
The Journal of thoracic and cardiovascular surgery 113 (1), 37-49, 1997
Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab …
DJ Slamon
Breast Cancer Res Treat 94, S5, 2005
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
C Desmedt, F Piette, S Loi, Y Wang, F Lallemand, B Haibe-Kains, G Viale, ...
Clinical cancer research 13 (11), 3207-3214, 2007
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study
C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ...
Journal of clinical oncology 24 (3), 394-400, 2006
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
M Dowsett, J Cuzick, J Ingle, A Coates, J Forbes, J Bliss, M Buyse, ...
Journal of Clinical Oncology 28 (3), 509-518, 2010
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
MEL Van Der Burg, M Van Lent, M Buyse, A Kobierska, N Colombo, ...
New England Journal of Medicine 332 (10), 629-634, 1995
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
S Loi, B Haibe-Kains, C Desmedt, F Lallemand, AM Tutt, C Gillet, P Ellis, ...
Journal of clinical oncology 25 (10), 1239, 2007
Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
Early Breast Cancer Trialists' Collaborative Group
New England journal of medicine 319 (26), 1681-1692, 1988
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
C Desmedt, B Haibe-Kains, P Wirapati, M Buyse, D Larsimont, ...
Clinical cancer research 14 (16), 5158-5165, 2008
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.
X Paoletti, K Oba, T Burzykowski, S Michiels, Y Ohashi, JP Pignon, ...
Jama 303 (17), 1729-1737, 2010
Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).
A Gerard, M Buyse, B Nordlinger, J Loygue, F Pène, P Kempf, JF Bosset, ...
Annals of surgery 208 (5), 606, 1988
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials
DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ...
Journal of Clinical Oncology 23 (34), 8664-8670, 2005
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials
D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ...
Journal of Clinical Oncology 27 (6), 872, 2009
The validation of surrogate endpoints in meta-analyses of randomized experiments
M Buyse, G Molenberghs, T Burzykowski, D Renard, H Geys
Biostatistics 1 (1), 49-67, 2000
The system can't perform the operation now. Try again later.
Articles 1–20